On 15 April 2026 Syn2bio joined the group of companies listed on the Warsaw Stock Exchange. Syn2bio’s stock market debut is the culmination of the process of dividing Synektik (listed on the WSE’s main market since 2014) into two separate companies. Syn2bio is a biotech company to which the business has been spun off connected with research on a cardiotracer and future commercialization of this innovative radiopharmaceutical for diagnosis of heart disease.
“The debut of Syn2bio on the Warsaw Stock Exchange is an important moment for the new company, but also a key step in the history of the Synektik Group,” said Cezary Kozanecki, founder and CEO of Synektik and CEO of Syn2bio. “It symbolically closes out the process of dividing Synektik into two independent entities. We spun off the cardiotracer project—our flagship R&D project—to Syn2bio. It will be the company’s task to further develop this innovative radiopharmaceutical and prepare for its commercialization. The division opens up for Syn2bio access to new sources of financing, including grants and programmes available for smaller entities. Synektik in turn will gain greater space for further strengthening of its profitability and growth of its own core business areas. We also believe that separating these two different business profiles will enable the market to more accurately assess the potential of each company.”
Cezary Kozanecki added: “The stock market debut isn’t the end of the road, but the start of a new stage. Syn2bio has further milestones ahead in connection with the cardiotracer, research, and the path to commercialization. What’s ahead for Synektik is further reinforcing of its position in areas where we have been effectively building value for years.”
Syn2bio’s stock market debut was preceded by an issue of 8,529,129 shares, which were allocated to Synektik shareholders in a 1:1 ratio. This means that for each Synektik share held at the end of the Record Date, which was set for 7 April, the investor received one share of Syn2bio. The last trading session when it was possible to buy Synektik shares entitled to participate in the division was on 1 April. Allocation of the shares occurred automatically and did not require any additional action by the shareholders.
The main business of Syn2bio is the continued development and commercialization of the cardiotracer project, and in the future also seeking innovative new pharmaceutical compounds. The other activity previously conducted by Synektik will remain in that company. It will thus continue to handle such matters as distribution and servicing of innovative medical equipment, development of its own IT solutions, and production and sale of radiopharmaceuticals.
